Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$193 Mln
P/E Ratio
--
P/B Ratio
2.31
Industry P/E
--
Debt to Equity
0.66
ROE
-0.55 %
ROCE
-37.34 %
Div. Yield
0 %
Book Value
2.2
EPS
-1.45
CFO
$-204.44 Mln
EBITDA
$-227.15 Mln
Net Profit
$-252.71 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Pulmonx Corp (LUNG)
| -33.43 | -39.89 | -29.38 | -39.08 | -45.06 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Pulmonx Corp (LUNG)
| -46.47 | 51.25 | -73.71 | -53.54 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.10 | 10,391.68 | 14.66 | 12.69 | |
| 71.01 | 9,766.86 | 94.68 | 2.52 | |
| 152.15 | 8,196.06 | -- | -25.23 | |
| 277.35 | 10,728.90 | 770.42 | 1.2 |
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis... Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. Address: 700 Chesapeake Drive, Redwood City, CA, United States, 94063 Read more
General Counsel & Secretary
Mr. David A. Lehman J.D.
General Counsel & Secretary
Mr. David A. Lehman
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Pulmonx Corp (LUNG) stood at $ 163 Mln as on 31-Dec-24
The share price of Pulmonx Corp (LUNG) is $4.52 (NASDAQ) as of 17-Apr-2025 16:07 EDT. Pulmonx Corp (LUNG) has given a return of -45.06% in the last 3 years.
Pulmonx Corp (LUNG) has a market capitalisation of $ 193 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Pulmonx Corp (LUNG) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Pulmonx Corp (LUNG) and enter the required number of quantities and click on buy to purchase the shares of Pulmonx Corp (LUNG).
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. Address: 700 Chesapeake Drive, Redwood City, CA, United States, 94063
The CEO & director of Mr. David A. Lehman J.D.. is Pulmonx Corp (LUNG), and CFO & Sr. VP is Mr. David A. Lehman.
There is no promoter pledging in Pulmonx Corp (LUNG).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| Pulmonx Corp (LUNG) | Ratios |
|---|---|
|
Return on equity(%)
|
-55.25
|
|
Operating margin(%)
|
-70.65
|
|
Net Margin(%)
|
-67.3
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Pulmonx Corp (LUNG) was $0 Mln.
$-0.27
(
